Patent application number | Description | Published |
20080228661 | SYSTEMS AND METHODS FOR PROVIDING FINANCIAL SERVICES - A new method and system for providing financial services is provided. These methods and systems can include providing banking and investment services to hedge fund money managers and other customers without the assistance or need for a prime broker. While employing the present invention a money manager may receive prime brokerage services from a bank or other financial service while at the same time be able to pursue investment opportunities with this bank or financial institution and other banks, institutions, and brokerages. The prime brokerage services that a money manger may receive can include accounting services, loan services, and cash management. | 09-18-2008 |
20080281751 | COLLATERAL REQUIREMENTS MATCHING AND DISPUTE RESOLUTION - A collateral management method for a plurality of parties, each of the parties having a collateral requirement with at least one other party of the plurality of parties is disclosed, the method including matching the collateral requirements of the plurality of parties to determine a net collateral requirement of a party of the plurality of parties to one or more other parties of the plurality of parties, and making available for that party the net collateral requirement of that party. | 11-13-2008 |
20110313906 | COMPUTER-INTEGRATED SECURITIES FINANCING SYSTEM AND METHOD - In one embodiment, a securities financing system integrates processing of both securities lending and repurchase (repo) agreement transactions conducted over a network. A securities financing platform has multiple modules and a management interface module through which input and output functions are provided to a system manager. Network communications are configured to manage respective data interfaces over the network with a first party borrower to the collateralized financial transaction, a second party lender to the collateralized financial transaction, and a central counterparty configured to provide trade netting and novation services to each of the first and second parties. A central counterparty interface is configured such that the central counterparty becomes a counterparty to each of the first party borrower and the second party lender through the securities financing system. | 12-22-2011 |
20140122372 | SYSTEMS AND METHODS FOR PROVIDING FINANCIAL SERVICES - A new method and system for providing financial services is provided. These methods and systems can include providing banking and investment services to hedge fund money managers and other customers without the assistance or need for a prime broker. While employing the present invention a money manager may receive prime brokerage services from a bank or other financial service while at the same time be able to pursue investment opportunities with this bank or financial institution and other banks, institutions, and brokerages. The prime brokerage services that a money manger may receive can include accounting services, loan services, and cash management. | 05-01-2014 |
Patent application number | Description | Published |
20090286817 | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use - Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders: | 11-19-2009 |
20100087433 | Methods of inhibiting tryptophan hydroxylase - Compounds, compositions and methods of treating serotonin-mediated diseases and disorders are disclosed. | 04-08-2010 |
20100280054 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE - Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: | 11-04-2010 |
20120041008 | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use - Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders: | 02-16-2012 |
20120157484 | TRYPTOPHAN HYDROXYLASE INHIBITORS - Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: | 06-21-2012 |
Patent application number | Description | Published |
20100041599 | Compositions and methods for bone formation, bone remodeling and toxin protection - The present invention identifies compounds that disrupt the interaction between anthrax proteins and LRP5/6 receptors, resulting in a reduction in anthrax toxicity. The compounds act to disrupt the intracellular transport of toxin complexes into a target cell. The present invention also provides methods for testing the effect of compounds on Wnt activity, through the use of in vitro experiments involving cells that have in at least one gene mutation involved in the Wnt pathway. | 02-18-2010 |
20100298200 | Compounds and assays for controlling Wnt activity - The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions. | 11-25-2010 |
20110105606 | Compositions and methods affecting the signaling pathways of LRP receptors - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 05-05-2011 |
20120184616 | Methods for treating inflammation - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 07-19-2012 |
20120322717 | Compounds and assays for controlling Wnt activity - The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions. | 12-20-2012 |
20130034866 | MULTISIGNAL REAGENTS FOR LABELING ANALYTES - Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule. | 02-07-2013 |
20140030787 | MULTISIGNAL REAGENTS FOR LABELING ANALYTES - Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule. | 01-30-2014 |
20150216832 | METHOD FOR TREATING INFLAMMATION BY ADMINISTERING A COMPOUND WHICH BINDS LDL-RECEPTOR-RELATED PROTEIN (LRP) LIGAND BINDING DOMAIN - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 08-06-2015 |
Patent application number | Description | Published |
20080248098 | Polysaccharide Microparticles Containing Biological Agents: Their Preparation and Applications - A method of preparing polysaccharide glassy microparticles which are less than 10 μum in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 μm in diameter containing delicate agents can be formed. These fine polysaccharide particles protect proteins within their hydrophilic glassy matrix, and can therefore be easily suspended in hydrophobic polymer solutions and formulated to various forms of sustained release devices such microsphere, sheets, fibers, coating layers, and scaffolds. The particles can also be dispersed in hydrophilic gels to improve releasing kinetics and to deliver vaccines and antibodies for immune therapy. | 10-09-2008 |
20090028904 | Novel cochleate formulations - A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 01-29-2009 |
20090036417 | COCHLEATES WITHOUT METAL CATIONS AS BRIDGING AGENTS - This invention provides a cochleate and nano-cochleate systems wherein the agents bridging lipid bilayer are organic multi-valent cations. This invention also provides a method for preparing the cochleate system comprising direct cochleation and hydrogel-isolated procedure. The preparation method comprises using the charge ration between the bridging agents and lipids to control the particle sizes. This cochleate or nano-cochleate system may be used for microencapsulation and delivery of therapeutics wherein the therapeutic agents are loaded in the cochleate structure as the bridging agents between lipid bilayers. Finally, this invention provides other uses of these new cochleate and nano- cochleate systems. | 02-05-2009 |
20110076307 | POLYCATIONIC GENE CARRIERS FORMED OF ENDOGENOUS AMINO GROUP-BEARING MONOMERS - The present invention is directed to a design of and a method to synthesize polycations for gene (DNA and RNA) delivery. According to this design, the polycations (also said cationic polymers) are formed by polymerization of endogenous monomers bearing sufficient amino groups through degradable bonds with linker molecules or with themselves. The amino group-bearing monomers are those naturally existing in or nontoxic to human body. The linker molecules are those which are not only degradable to nontoxic fragments but also able to release the amino group-bearing monomers in their native state upon degradation. Some examples for the endogenous amino group-bearing monomers are spermine, spermidine, serine or N,N-dimethyl serine, and histidine. Examples for the degradable chemical bonds formed between the amino group-bearing monomers are carbamate, imine, amide, carbonate, and ester. In order to improve degradability or proton sponging effect, low pKa (<8) amino group(s) or other electron donating group(s) is incorporated in the linker between the two (or three) reactive groups for linking the amino group-bearing monomers. These polycationic carrier systems can be used for nano-encapsulation and transfection of gene materials. | 03-31-2011 |
20120294901 | NOVEL COCHLEATE FORMULATIONS - A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 11-22-2012 |
20140220109 | NOVEL COCHLEATE FORMULATIONS - A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 08-07-2014 |
Patent application number | Description | Published |
20140109223 | PROVIDING A REAL-TIME ANOMALOUS EVENT DETECTION AND NOTIFICATION SERVICE IN A WIRELESS NETWORK - A method and apparatus for providing a notification service in a wireless network are disclosed. For example, the method registers a mobile device associated with a customer for the notification service, collects traffic data related to the mobile device of the customer, determines if an anomaly is detected for the traffic data that is collected for the mobile device, and provides a notification to the mobile device of the customer, if the anomaly is detected for the traffic data that is collected for the mobile device. | 04-17-2014 |
20140370843 | MANAGEMENT OF GROUP MOBILE DEVICE NETWORK TRAFFIC USAGE - Network traffic usage information for a set of registered devices is monitored, analyzed, and reported within a cellular service provider portion of a communications network. The network traffic usage information can relate to data traffic, voice traffic, and/or short message service traffic. Reporting the network traffic usage information is customizable such that parameters associated with the network traffic usage can be changed, depending on the parameters that are of current interest to an organization affiliated with the set of registered devices. | 12-18-2014 |
20150148006 | System and Method for Crowd-Sourcing Mobile Messaging Spam Detection and Defense - A crowd-sourced mobile messaging spam detection and defense system includes an application running on a mobile device. The application uses an unwanted message detection algorithm to analyze and classify messages as potential unwanted messages. The potential unwanted messages are presented to a user for confirmation that the messages are unwanted messages. In response to confirmation, the mobile device transmits a notification to a virtual machine associated with the user. The virtual machine uses the notification to update the unwanted message detection algorithm which may then be transmitted to the mobile device. The virtual machine may also transmit the notification to a global virtual machine. The global virtual machine may use the notification to update a set of classification rules maintained by the global virtual machine and transmit the set of classification rules as necessary to the multiple virtual machines for use in updating the unwanted message detection algorithm. | 05-28-2015 |
20150319586 | System and Method for Fast and Accurate Detection of SMS Spam Numbers Via Monitoring Grey Phone Space - A method and system for identifying short message service (SMS) spammers identifies senders as spammers by determining that the senders are sending SMS messages to devices included in a grey phone space. Devices in the grey phone space are identified using various methods including an analysis of call detail records. A grey ratio for a sender is determined as a ratio of messages sent to grey phone numbers by the sender to messages sent to all phone numbers by the sender. A sender is identified based on a difference between the grey ratio for the sender and a second grey ratio being above a threshold. | 11-05-2015 |
Patent application number | Description | Published |
20120150129 | Non-Luer Connectors - Drug delivery devices having integrated non-luer connectors are described. An exemplary drug delivery device includes a container with a non-luer connector that prevents connection of a standard female luer connector to the container. One or more embodiments pertain to a container with a non-luer connector that prevents the formation of a fluid-tight seal between a standard female luer connector and the container. A non-luer connector for attachment to a container having a non-luer element is also described. | 06-14-2012 |
20130267907 | Blunt Needle Safety Drug Delivery System - Drug delivery devices having non-luer connections and adapters and adaption connectors for providing non-luer connections to drug delivery devices are provided. An exemplary drug delivery device for use with a catheter connection includes a blunt needle component with a non-luer connection and a filter component with a non-luer connection, wherein the non-luer connections of the blunt needle component and filter component are incompatible with standard luer fitting and intravenous route-accessing devices. In one or more embodiments, an adapter having a non-luer connection at one end and a luer connector is provided for use with blunt needle components and filter components wherein one of the blunt needle component and the filter component includes a luer connection and the other of the blunt needle component and the filter component includes a non-luer connection. Methods of delivering liquid medication to a catheter are also provided. | 10-10-2013 |
20140107572 | VALVE SYSTEM FOR INFLATABLE MEDICAL DEVICE - The present invention relates to a valve system for an inflatable portion of an indwelling medical device and more particularly to a valve system for fluid regulation of a catheter comprising a fluid inflatable portion that undergoes pressure changes within the body during use. The present invention also relates to methods of treatment using said valve system and indwelling medical devices comprising said valve systems. | 04-17-2014 |
20150051542 | APPARATUS FOR PREVENTING OVER INFLATION OF THE RETENTION BALLOON IN MEDICAL CATHETERS AND AIRWAY DEVICES - The body has a fluid inlet port for receiving pressurized fluid and a fluid outlet port connected to the retention balloon. A first passage connects the fluid inlet port and the fluid outlet port. A second passage in the body is connected to the balloon fluid return path and is at the pressure of the retention balloon. A valve prevents fluid flow through the first passage when actuated. The valve includes a pressure-responsive member movable to a position to obstruct fluid flow in response to fluid pressure in the second passage exceeding the predetermined level. Flexible means such as a membrane defines a normally open portion of the first fluid passage, which is closed by the moveable means bearing on the membrane when pressure exceeding the predetermined level actuates the valve. | 02-19-2015 |
20150059901 | SELF-CLOSING BAG CONNECTOR - A bag connector system includes a first coupling element, with a self-closing seal and a housing having a fluid inlet port and a fluid outlet port, and a second coupling element, with a housing having a fluid inlet end and a fluid outlet end. The fluid inlet end is configured to displace the self-closing seal when inserted into the fluid outlet port of the first coupling element. A bag connector system optionally includes a locking mechanism to maintain the first coupling element and second coupling element in a coupled state. Uncoupling of the first and second coupling elements results in minimal fluid contamination on the outer surfaces of the coupling elements. The bag connector systems provided herein are included in medical appliances for waste management. | 03-05-2015 |
20150157848 | Safety Drug Delivery Connectors - Drug delivery connectors are provided for permitting and blocking fluid flow between a container and a catheter connector or other drug delivery site. Embodiments of the drug delivery connectors include a ball valve for forming a releasable seal within the drug delivery connectors. In one or more embodiments, the ball valve prevents fluid flow between an open proximal end and an open distal end of the drug delivery connector and is movable in a proximal direction to release the releasable seal to permit fluid flow from the open proximal direction to the open distal direction. Methods of delivering medication to a catheter connector that includes an actuator are also provided | 06-11-2015 |
Patent application number | Description | Published |
20110208128 | Safety Drug Delivery Connectors - Drug delivery connectors are provided for permitting and blocking fluid flow between a container and a catheter connector or other drug delivery site. Embodiments of the drug delivery connectors include a ball valve for forming a releasable seal within the drug delivery connectors. In one or more embodiments, the ball valve prevents fluid flow between an open proximal end and an open distal end of the drug delivery connector and is movable in a proximal direction to release the releasable seal to permit fluid flow from the open proximal direction to the open distal direction. Methods of delivering medication to a catheter connector that includes an actuator are also provided | 08-25-2011 |
20110208160 | Safety Drug Delivery System - Drug delivery systems are provided that include an actuator assembly permanently attached to a filter for connection of a container containing medications such as epidural anesthesia, to a delivery site. In one or more embodiments, the actuator assembly includes a projection with an opening extending from a distal end of the actuator assembly in a proximal direction and the filter includes an inlet and an outlet in fluid communication with the opening. The filter includes a housing including two plates joined together or a cylindrical body defining a cavity containing filter materials. A conduit may be attached to the outlet of the filter to allow connection of the drug delivery systems described to a delivery site, such as a catheter. Methods of administering a medication to a delivery site are also provided. | 08-25-2011 |
20120029465 | Blunt Needle Safety Drug Delivery System - Drug delivery devices having non-luer connections and adapters and adaption connectors for providing non-luer connections to drug delivery devices are provided. An exemplary drug delivery device for use with a catheter connection includes a blunt needle component with a non-luer connection and a filter component with a non-luer connection, wherein the non-luer connections of the blunt needle component and filter component are incompatible with standard luer fitting and intravenous route-accessing devices. In one or more embodiments, an adapter having a non-luer connection at one end and a luer connector is provided for use with blunt needle components and filter components wherein one of the blunt needle component and the filter component includes a luer connection and the other of the blunt needle component and the filter component includes a non-luer connection. Methods of delivering liquid medication to a catheter are also provided. | 02-02-2012 |